Treatment of Resectable Gallbladder Carcinoma With No Metastatic Spread

This protocol addresses the management of gallbladder carcinoma (GBC) confirmed to have no metastatic spread and assessed as surgically resectable. Evaluation of resectability is the central step guiding the treatment pathway in this setting.

Clinical Scenario

Patients present with gallbladder carcinoma without evidence of distant metastatic disease. Resectability assessment is the key factor at diagnosis — particularly for those identified during imaging or presenting with jaundice.

Surgery is the only currently available modality with curative potential and the treatment plan should be established by a specialist hepatobiliary multidisciplinary tumour board.

Treatment Approach

Following surgical resection, the treatment approach in selected patients may involve a course of adjuvant systemic therapy, with a role for radiotherapy in certain resection margin scenarios — the full regimen and eligibility criteria are in the structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

If GBC is diagnosed during imaging (for symptomatic patients) or when patients present with jaundice, evaluation of potential resectability is the key factor.

Surgery is, at present, the only modality that can cure BTC and should be agreed by a specialist hepatobiliary multidisciplinary tumour board.

RT, after completion of adjuvant capecitabine, might be considered in selected patients (R1 resection of GBC or d/pCCA).

DOI: 10.1016/j.annonc.2022.10.506

View source ↗